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Summary
Objective.— Most evidence-based practice guidelines identify low-density lipoprotein choles-
terol (LDL-C) as the primary target of cholesterol-lowering therapy; the optimal LDL-C
concentration is based on the patient’s individual risk level. The aim of this study was to deter-
mine the proportion of patients on lipid-lowering drugs who reach the LDL-C goals recommended
in guidelines.
Methods.— The CEPHEUS study was conducted in eight European countries in patients, who had
been treated with lipid-lowering drugs for at least three months, with no dose adjustment for
a minimum of six weeks. In France, throughout 2006, 560 general practitioners enrolled 2222
patients into the study, 1966 of whom gave a fasting blood sample. Lipid and glucose parameters
were measured centrally.
Results.— Patients had been on treatment for a mean of 5.5± 5.7 years. Most patients (90.4%)
received a single lipid-lowering drug; 84.9% were treated with statins, and the second most
frequently used lipid-lowering drugs were ﬁbrates (13.7%). Among the treated subjects, 50% had
LDL-C values >3.0mmol/L, 30% had triglyceride values >1.7mmol/L and 10% had HDL cholesterol
values < 1.1mmol/L. In high-risk patients, as deﬁned by French guidelines, over 55% were above
the recommended goal of 2.6mmol/L. In the subgroup of high-risk patients who did not reach
the goals, the LDL-C values were 0.7—1.4mmol/L over the recommended concentration.
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Conclusion.— Cette étude montre le contrôle sous-optimal de l’hypercholestérolémie en France
et ce, plus particulièrement chez les sujets à haut risque cardiovasculaire qui atteignent moins
uils r
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bbreviations
fssaps Agence franc¸aise de sécurité sanitaire des produits
de santé
VD cardiovascular disease
DL-C high-density lipoprotein cholesterol
DL-C low-density lipoprotein cholesterol
C total cholesterol
JETF Third Joint European Task Force
ackground
revention of cardiovascular disease in an individual patient
s based on simultaneous management of all of their risk
actors. Preventive actions show the greatest degree of
eneﬁt when the risk of cardiovascular events is high.
he most recent guidelines from the European Society of
ardiology have reasserted the need to control all risk
actors, especially in high-risk patients [1]. These guide-
ines recommend that the concentration of low-density
ipoprotein cholesterol (LDL-C) remains below 3mmol/L.
n France, guidelines on lipid management are published
egularly by the Agence franc¸aise de sécurité sanitaire
es produits de santé (Afssaps) [2]. Thus it is impor-
ant to evaluate contemporary clinical practice patterns
elating to these guidelines, in order to ensure that
atients beneﬁt from the latest improvements seen in
r
m
w
cecommandées.
rights reserved.
he management of dyslipidaemia-induced cardiovascular
isk.
Quantitative evaluation of plasma lipid concentrations is
undamental for the accurate assessment of medical prac-
ice and its appropriateness with regard to guidelines. The
istribution of lipids levels in a representative sample of the
rench population on lipid-lowering therapy, and the evalu-
tion of lipid-lowering drugs in relation to the 2000 Afssaps
uidelines, became available for the ﬁrst time in the Suivi
es pratiques vers les objectifs thérapeutiques (SPOT) study
3]. A new recommendation for lipid management was issued
y Afssaps in March 2005 [2]. Thus, the multinational Euro-
ean CEPHEUS study was carried out to assess the agreement
etween results obtained with lipid-lowering drugs in France
nd the Afssaps guidelines issued in 2005, with a precise and
entralized quantiﬁcation of plasma lipids.
ethods
‘CEPHEUS’’ was a multinational survey conducted in eight
uropean countries: Belgium, France, Greece, Ireland, the
etherlands, Finland, Turkey and Luxembourg. To obtain aJ. Ferrières et al.
Conclusion.— The results of this survey highlight the suboptimal management of hypercholes-
terolaemia in France, particularly in the high-risk population, in whom the percentage who
achieved the LDL-C goals was the lowest.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
But de l’étude.— La plupart des recommandations identiﬁent le LDL-cholestérol (LDL-C)
comme cible thérapeutique des agents hypolipémiants et recommandent des objectifs de LDL-
C basés sur la catégorie de risque à laquelle appartient le patient. Le but de cette étude a
été d’évaluer la proportion de patients sous traitement hypolipémiant atteignant les seuils de
LDL-C recommandés.
Méthodes.— Cette étude porte sur des patients sous traitement hypolipémiant depuis au moins
trois mois sans changement de dose depuis au moins six semaines. Cette étude a été menée
dans huit pays européens. En France, 560 médecins généralistes ont inclus 2222 patients en
2006. Parmi les patients qui ont consenti à participer, 1966 ont eu un prélèvement biologique
à jeun. Les paramètres lipidiques et la glycémie ont été mesurés de manière centralisée.
Résultats.— Les patients étaient traités en moyenne depuis 5,5± 5,7 ans. La plupart des
patients (90,4 %) ont rec¸u une monothérapie hypolipémiante ; 84,9 % étaient traités par sta-
tine, le second hypolipémiant le plus fréquemment utilisé était représenté par les ﬁbrates
(13,7 %). Parmi ces sujets traités, 50 % avaient des valeurs de LDL-C au-dessus de 3,0mmol/L,
30 % avaient des valeurs de triglycérides au-dessus de 1,7mmol/L et 10 % avaient des valeurs
de HDL-cholestérol en dessous de 1,1mmol/L. Chez les sujets à haut risque déﬁni selon les
recommandations franc¸aises, plus de 55% des patients se situaient au-dessus de la valeur recom-
mandée de LDL-C de 2,6mmol/L. Dans le sous-échantillon des sujets à haut risque qui n’avaient
pas atteint l’objectif recommandé, les valeurs de LDL-C étaient de 0,7 à 1,4mmol/L plus élevées
que les valeurs recommandées.epresentative sample of subjects on lipid-lowering treat-
ent, individuals were randomly invited to participate.
In France, the study protocol and informed consent form
ere approved on 5 May 2006 by the Toulouse-2 Comité
onsultatif de protection des personnes dans la recherche
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Table 1 Patients’ baseline characteristics.
Survey cohort (n = 1966)
Age (years)a 62.7± 11.1
Men (%) 1027 (55.7)
Body mass index (kg/m2)a 27.58± 4.80
Waist circumference (cm)a 96.4± 12.8
Systolic blood pressure
(mmHg)a
133.1± 11.9
Diastolic blood pressure
(mmHg)a
77.6± 7.9
History of coronary heart
disease (%)
339 (18.4)
History of peripheral
artery disease (%)
214 (11.6)
History of coronary artery
disease (%)
75 (4.1)
Current smoker (%) 263 (14.3)
Diabetes (%) 315 (17.1)
Hypertension (%) 1089 (59.1)
Family history of
premature
cardiovascular disease
(%)
514 (28.0)
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biomédicale. The survey was performed in accordance with
the Declaration of Helsinki and was consistent with the
International Conference on Harmonisation of Good Clinical
Practice guidelines. Signed and dated informed consent was
obtained from all participants before conducting any proce-
dures speciﬁc to the survey. The principal investigator was
responsible for storing the original signed informed consent
form and a copy was given to the subject.
Before any patients were recruited, each investigator
completed a questionnaire on their experience of and atti-
tude towards the management of hypercholesterolaemia.
The form included questions on the diagnosis of hypercholes-
terolaemia, on guidelines and goals, and on the treatment
options available.
Adult (≥ 18 years) men and women were eligible for the
study. The inclusion criteria were: lipid-lowering treatment
for a minimum of three months before enrolment, with no
dose adjustment for at least six weeks; and patients who
beneﬁtted from French National Health Insurance. For each
subject, the investigator completed a patient record form,
which collected the following information:
• screening and demographic data (date of birth, sex and
ethnic group);
• results of physical examination (height, weight, waist cir-
cumference, blood pressure);
• history of cardiovascular disease (CVD), peripheral artery
disease, and cerebrovascular atherosclerotic disease;
• presence of CVD risk factors (current smoking, dia-
betes, family history of premature coronary heart disease
[deﬁned as deﬁnite myocardial infarction or sudden death
before 55 years of age in father or other male ﬁrst-
degree relative, or before 65 years of age in mother or
other female ﬁrst-degree relative], arterial hypertension
[deﬁned as blood pressure ≥ 140/≥ 90mmHg or current
use of antihypertensive medication]);
• hypercholesterolaemia and year drug treatment was
started, if known;
• fasting blood sample;
• current lipid-lowering pharmacological treatment; and
• rationale for prescribing current lipid-lowering therapy
(familial hypercholesterolaemia, primary or secondary
prevention).
A fasting blood sample was also taken. Within 2—5 days
after the visit, the investigator received the patient’s results
as well as the 2005 Afssaps guidelines (current French guide-
lines) by fax. This allowed the investigator to determine the
patient’s risk proﬁle and take the appropriate measures, if
any, with respect to the patient’s future treatment. In addi-
tion, the investigator was provided with the patient’s CVD
risk proﬁle after the data for that particular individual had
been entered in the database.
Efﬁcacy measurements
The primary efﬁcacy variable was the percentage of sub-
jects achieving LDL-C goals according to the Third Joint
European Task Force (TJETF) guidelines [4]. One of the sec-
ondary efﬁcacy variables was the percentage of subjects
achieving LDL-C goals according to the 2005 Afssaps guide-
lines [2]. In order to evaluate this endpoint, blood plasma
a
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aa Mean± standard deviation.
evels were determined for total cholesterol (TC), LDL-C,
igh-density lipoprotein cholesterol (HDL-C), triglycerides,
lucose, apolipoprotein A-1 and apolipoprotein B. A total of
mL blood was drawn into a gel tube and a further 2mL into
ﬂuoride tube using the materials provided by the central
aboratory. The tubes were mixed by gentle inversion and
hipped to the central laboratory by air courier. Laboratory
nalyses were performed at Quintiles Laboratories Europe
1 Simpson Parkway, Livingston, UK).
tatistical analysis
he full dataset for this analysis consisted of all patients
rom the French enrolling centres, who gave their informed
onsent and underwent a laboratory test. Most investigators
88.8%) used guidelines to establish individual target choles-
erol levels; the most frequently used were the Afssaps
uidelines (90.9% of investigators). Other, less often used,
uidelines were TJETF (17.9%), National Cholesterol Educa-
ional Program Adult Treatment Panel III guidelines (16.1%),
nd individual practice guidelines (21.2%). We therefore
nalysed LDL-C goals according to the Afssaps guidelines,
hich are the main tool for evaluating lipid-lowering treat-
ent in France. For each patient, the Afssaps risk category
as determined and a dichotomous variable computed indi-
ating whether the patient had achieved their LDL-C goal,
orresponding to risk category. The percentage of subjects
chieving LDL-C goals according to Afssaps guidelines was
hen reported.
A two-level logistic regression analysis was performed to
etermine the prognostic factors for achieving LDL-C goals
ccording to the Afssaps guidelines, with patients at the
560 J. Ferrières et al.
Table 2 Distribution of biological parameters in treated subjects (n = 1966) based on central laboratory determination.
Percentiles
n Missing 10th 20th 30th 40th 50th 60th 70th 80th 90th
Total cholesterol
(mmol/L)
1959 7 3.97 4.38 4.64 4.92 5.21 5.44 5.72 6.03 6.62
High-density
lipoprotein
cholesterol (mmol/L)
1959 7 1.06 1.16 1.26 1.37 1.47 1.55 1.68 1.83 2.09
Low-density lipoprotein
cholesterol (mmol/L)
1957 9 1.91 2.27 2.50 2.76 2.96 3.17 3.43 3.74 4.20
Triglycerides (mmol/L) 1959 7 0.77 0.92 1.05 1.19 1.34 1.52 1.75 2.09 2.61
Apolipoprotein A-1
(g/L)
1938 28 1.25 1.35 1.43 1.50 1.57 1.65 1.72 1.84 1.99
.72
.79
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Glucose (mmol/L) 1960 6 4.57 4
rst level and physicians at the second level. This study had
hierarchical design with a two-tiered structure. Patients
ere clustered by physician practice, as patients from the
ame practice were more likely to be treated similarly com-
ared with patients from other practices, and as optimal
ipid treatment is likely to reﬂect a physician’s therapeutic
ehaviour. A multiple logistic regression model on the com-
ined data assumed observations were uncorrelated. In case
f multilevel data, this assumption was unrealistic and fail-
re to take into account the hierarchical data structure may
ave led to underestimation of standard errors. Hence, the
ata were analysed by a two-level logistic regression model
ith the dependent variable (achievement of LDL-C goals
ccording to Afssaps guidelines [yes vs no]) and ﬁxed effects
the potential predictors] and a random effect [physicians]).
Association was appraised by an estimated odds ratio
ith associated 95% conﬁdence intervals and P values in
he ﬁxed-effects part of the models. All predictors with P
alue < 0.10 (using a Wald-type test) in this raw association
nalysis were then included in an adjusted multilevel logis-
ic regression model, provided that at least 90% of data were
vailable. Multilevel analysis was performed using SAS PROC
LIMMIX (Cary, NC, USA).esults
n the French arm of the CEPHEUS study, 560 general prac-
itioners enrolled 2222 patients between September and
d
t
d
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Table 3 Low-density lipoprotein cholesterol (LDL-C) by risk c
LDL-C (mmol/L) Risk categories according to
High risk
(n = 417)
(%)
≥ 3 risk
factors (n = 24)
(%)
2 risk fact
(n = 38) (%
2.6—3.4 250 (60.0) 0 (0.0) 0 (0.0)
3.4—4.1 102 (24.5) 16 (66.7) 0 (0.0)
4.1—4.9 49 (11.8) 5 (20.8) 28 (73.7)
4.9—5.7 13 (3.1) 3 (12.5) 7 (18.4)
≥ 5.7 3 (0.7) 0 (0.0) 3 (7.9)0.79 0.84 0.89 0.94 1.00 1.09 1.22
5.01 5.17 5.34 5.56 5.83 6.27 7.26
ecember 2006. Among consenting patients, 256 patients
id not undergo a laboratory test. Laboratory data were
vailable for the remaining 1966 patients, who constitute
he study population.
Patients’ characteristics are given in Table 1. The preva-
ences of men older than 50 years or women older than
0 years were 86.4% and 67.2%, respectively. Patients had
een on treatment for a mean of 5.5± 5.7 years. The
ost frequent indication for treatment prescription was
rimary prevention (74.1%), followed by secondary pre-
ention (21.8% patients) and familial hypercholesterolemia
4.1% patients, not included in the French guidelines). Most
atients (90.4%) received a single lipid-lowering drug. Of
hese, the majority (84.9%) were treated with statins. The
econd most commonly used lipid-lowering therapy was
brate (13.7%). No patients were treated with bile acid
equestrants, while 25 (1.4%) were treated with ezetimibe
s monotherapy. Among the statins used as monotherapy,
osuvastatin was the most frequently used (24.1%), followed
y atorvastatin (20.8%) and pravastatin (17.9%). The ﬁbrate
ost frequently prescribed as monotherapy was fenoﬁbrate
11.4%) followed by bezaﬁbrate (1.0%) and ciproﬁbrate
1.0%). All patients treated with multiple lipid-lowering
herapies (n = 66) received a statin in combination with other
rugs.
The average TC values were 5.27± 1.06mmol/L and
he LDL-C values were 3.03± 0.92mmol/L. The complete
istributions for lipid parameters are shown in Table 2.
mong these treated subjects, 50% had LDL-C values above
ategory in patients who did not reach target levels.
2005 Afssaps guidelines Total (n = 501)
ors
)
1 risk factor
(n = 17) (%)
No risk factors
(n = 5) (%)
0 (0.0) 0 (0.0) 250 (49.9)
0 (0.0) 0 (0.0) 118 (23.6)
0 (0.0) 0 (0.0) 82 (16.4)
14 (82.4) 0 (0.0) 37 (7.4)
3 (17.6) 5 (100.0) 14 (2.8)
Assessment of lipid-lowering treatment in France — The CEPHEU
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In France, very few studies have assessed the resultsFigure 1. Achievement of low-density lipoprotein cholesterol
goals according to the 2005 Afssaps guidelines, by risk category.
3.0mmol/L, 30% had TG values above 1.7mmol/L, 10% had
HDL-C values below 1.1mmol/L and 40% had HDL-C values
above 1.55mmol/L. Most physicians reported schedul-
ing cholesterol-monitoring consultations every six months
(48.9%) or once a year (35.9%). Only 13.5% of investigators
reported scheduling follow-up visits every three months.
Among the patients evaluated, 41.8% reached the LDL-C
goals recommended in the TJETF guidelines. The percent-
age of subjects achieving LDL-C goals according to Afssaps
guidelines are shown in Fig. 1. In high-risk subjects (44.8%
with coronary heart disease, 33.7% with high-risk diabetes
[deﬁned as diabetes with at least two classical risk fac-
tors] and 37.5% with a Framingham risk score ≥ 20%), more
than 55% of patients were above the recommended goal of
2.6mmol/L. In the subgroup of patients, who did not reach
LDL-C goals, we assessed the distribution of LDL-C values
within each Afssaps category (Table 3). Patients, who did
not reach the target levels had LDL-C values 0.7—1.4mmol/L
higher than the recommended Afssaps goal.
The prognostic factors for achieving LDL-C goals accord-
ing to the Afssaps guidelines, in an adjusted multilevel
logistic regression model, are given in Table 4. When
patients were stratiﬁed according to risk category, the per-
centage who reached the target was well correlated with
their CVD risk level (i.e. the higher the CVD risk, the lower
the percentage of patients on target).
Discussion
The CEPHEUS study, conducted in 2006, conveys new
information about the current management of hypercholes-
terolaemia in France. These data show that the distribution
of LDL-C levels in France has not changed since 2003, with
50% of treated patients having levels higher than 3mmol/L.
Of concern, 55% of high-risk patients have LDL-C levels above
2.6mmol/L. Furthermore in each class, deﬁned according to
the Afssaps guidelines, LDL-C levels in subjects not reaching
the target were 0.7—1.4mmol/L higher than the recom-
mended values.
Evidence concerning the efﬁcacy of lipid-lowering
treatment, and more particularly of statins, in treating car-
o
u
r
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iovascular risk is ample in the ﬁelds of both secondary
nd primary prevention [5]. Follow-up studies of random-
zed controlled trials [6—8] have shown that in patients
nitially treated with statins, the beneﬁcial effects of the
herapy remained even after statin discontinuation. Statins
ave a large number of targets in atherosclerosis, but their
mpact on atheroma plaques seems irrefutable [9—11]. The
nti-inﬂammatory pleiotropic effects of statins are still
ebated and are speciﬁcally being investigated [12]. On
n epidemiological level, the beneﬁcial effects of lipid-
owering treatment targeting hypertriglyceridaemia and/or
ow HDL-C levels seem quite compelling but, so far, addi-
ional efﬁcacy demonstrations from prospective trials with
ard clinical end-points are severely lacking [13—16]. In
008, lipid-lowering treatment should be based mainly on
tatins, despite alternative therapies in very speciﬁc situa-
ions [17].
Compared with the only quantitative evaluation carried
ut in a French population [3], the French arm of the Euro-
ean CEPHEUS study showed no improvement in LDL-C levels
ver a three-year period. This goes against the recommen-
ations for optimizing lipid-lowering treatment imparted in
nternational guidelines [1,18], advising aggressive treat-
ent for high-risk patients as well as aiming to decrease
verall lipid levels. In France, the situation is complex
ue to a speciﬁc recommendation tolerating relatively ele-
ated LDL-C levels for low-risk subjects (< 4.9mmol/L and
5.7mmol/L). With no absolute cause—effect relationship,
he LDL-C distribution did not change between 2003 and
006. One may wonder about the impact of this overall lack
f improvement on the global distribution of cardiovascular
isk. In any event, 50% of French patients are treated incor-
ectly according to European guidelines. The medical and
conomic impact caused by this situation should be docu-
ented further since lifelong low LDL-C is connected with
etter long-term prognosis [19].
In France, once low-risk patients (correctly treated) are
ot taken into account since thresholds are rather high
< 4.9mmol/L and < 5.7mmol/L), high-risk patients’ con-
itions are even worse. In March 2005, this category of
atients was redeﬁned in the guidelines [2], including all
ardiovascular pathologies and subjects with high absolute
ardiovascular risk (Framingham risk score > 20% over a 10-
ear period). In this new context, the LDL-C levels of 55%
f high-risk patients were above the recommended thresh-
ld of 2.6mmol/L in the present study. The likelihood of
chieving this threshold depends markedly on LDL-C level
t baseline in a given subject and on the potency of the
tatin used. To treat high-risk normolipidaemic subjects, any
tatin with the dosage used in randomized controlled tri-
ls would be adequate. In patients with high LDL-C levels,
owever, precise assessment of LDL-C levels in the CEPHEUS
tudy showed that to reach the recommended threshold, an
dditional decrease of 0.7—1.4mmol/L would be necessary.
onsequently, physicians should not hesitate to titrate the
urrent statin or to prescribe a more potent statin to lower
DL-C levels.f lipid-lowering drugs in relation to measured LDL-C val-
es. Recently, the EUROASPIRE III study (unpublished data)
eassessed the results of lipid-lowering treatment in a sam-
le of 270 coronary patients in the region of Lille (Lille,
562 J. Ferrières et al.
Table 4 Predictors of achieving LDL-C goals according to the 2005 Afssaps guidelines: results of multilevel logistic
regression.
Factor Odds ratio 95% CI P value
Age (vs < 40 years) 0.034
40—54 0.76 (0.35—1.65)
55—69 0.62 (0.29—1.33)
70—79 0.47 (0.21—1.02)
≥ 80 0.44 (0.18—1.06)
Female (vs male) 1.56 (1.24—1.96) 0.0002
Current smoker (vs no) 0.48 (0.35—0.65) < 0.0001
Diabetes (vs no) 0.56 (0.43—0.73) < 0.0001
Hypertension (vs no) 0.59 (0.47—0.75) < 0.0001
.64
.32
.62
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Secondary prevention (vs primary) 0
High triglycerides levels (vs no) 0
omme, Roubaix, Tourcoing). Since medical practice varies
etween regions [20], a large population sample would be
ecessary to draw a relevant conclusion, irrespective of the
isk categories deﬁned by the Afssaps. Moreover, declarative
ata concerning LDL-C may introduce a bias that cannot be
ectiﬁed by statistical analysis.
tudy limitations
espite the rather large sample size, the study population
as not representative of all treated patients in France.
oreover, the inclusion criteria required stable treatment
ver a period of six weeks before entry into the study. The
rench situation with regard to the Afssaps guidelines is
robably worse since the most unstable patients — those
ot adhering to treatments and patients who are the most
ifﬁcult to treat— were excluded. Furthermore, blood sam-
les were required for this study, which probably limited
he participation of some patients and/or physicians. Con-
ersely, the Afssaps guidelines focused on LDL-C whereas
lobal lipid-related cardiovascular risk goes beyond the eval-
ation of this sole parameter. In particular, in the CEPHEUS
tudy 30% of treated patients had triglyceride values above
.7mmol/L and 10% had HDL-C values less than 1.1mmol/L.
hus, an over-risk exists due to residual dyslipidaemia in a
arge number of patients. Lastly, we did not assess medi-
ation compliance, which is why, in speciﬁc patients, high
DL-C values may reﬂect poor compliance to lipid-lowering
reatment.
onclusions
his is the second study to provide a quantitative evaluation
f the results of lipid-lowering treatment in French patients.
hile low-risk patients were treated in accordance with the
uidelines, high-risk patients were inadequately treated.
rug titration and the use of more potent lipid-lowering
rugs, combination therapy or a more holistic approach
such as patient education) are avenues worth exploring. In
he meantime, patients at very high risk should be treated
ntensively by physicians, since they are more likely to be at
isk of new or recurrent cardiovascular events in the short-(0.5—0.81) 0.0002
(0.25—0.4) < 0.0001
(0.5—0.78) < 0.0001
erm. Further quantitative evaluations of plasma lipids in
atients on lipid-lowering treatment are needed to assess
rench medical practices.
unding
he CEPHEUS study was sponsored by Astra Zeneca. This
anuscript was prepared by Jean Ferrières who is not gov-
rned by the funding support. Elisabeth Tocque-Le Gousse
nd Caroline Fabry had the opportunity to review the
anuscript but did not have the authority to change the
ontent.
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